ASTRAZENECA PLC ADR

NASDAQ: AZN (Astrazeneca PLC)

Kemas kini terakhir: 23 Sep, 5:02PM

77.14

-1.24 (-1.58%)

  • 1H -1.58%
  • 5H 14.45%
  • 1B 20.04%
  • 6B -2.21%
  • Tahun Ke Tarikh 12.78%
  • 1T 16.35%
  • 5T 54.62%
Penutupan Terdahulu 78.38
Buka 77.24
Jumlah Dagangan 3,788,214
Purata Dagangan (3B) 4,388,519
Modal Pasaran 239,634,644,992
Harga / Pendapatan (P/E TTM) 37.45
Harga / Pendapatan (P/E Ke hadapan) 14.58
Harga / Jualan (P/S) 4.16
Harga / Buku (P/B) 5.19
Julat 52 Minggu
60.47 (-21%) — 87.68 (13%)
Tarikh Pendapatan 12 Nov 2024
Hasil Dividen (DY TTM) 1.93%
Margin Keuntungan 12.68%
Margin Operasi (TTM) 20.40%
EPS Cair (TTM) 2.07
Pertumbuhan Hasil Suku Tahunan (YOY) 18.00%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 4.00%
Jumlah Hutang/Ekuiti (D/E MRQ) 77.47%
Nisbah Semasa (MRQ) 0.930
Aliran Tunai Operasi (OCF TTM) 11.33 B
Aliran Tunai Bebas Leveraj (LFCF TTM) 9.51 B
Pulangan Atas Aset (ROA TTM) 8.50%
Pulangan Atas Ekuiti (ROE TTM) 16.66%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Drug Manufacturers - General (US) Menaik Menaik
Drug Manufacturers - General (Global) Menaik Menaik
Stok Astrazeneca PLC Menaik Menaik

AISkor Stockmoo

1.3
Konsensus Penganalisis 2.0
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 1.5
Osilator Teknikal -0.5
Purata 1.25

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
AZN 240 B 1.93% 37.45 5.19
SNY 120 B 8.54% 25.24 1.55
AMGN 143 B 3.38% 34.01 18.81
GILD 113 B 3.40% 1,005.44 6.21
GRFS 6 B - 32.20 0.830
BIIB 23 B - 14.35 1.31

A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Sektor Healthcare
Industri Drug Manufacturers - General
Gaya Pelaburan Large Growth
% Dimiliki oleh Institusi 16.76%

Tiada data dalam julat masa ini.

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
18 Dec 2024 CNBC Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal
12 Dec 2024 Pengumuman Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development
11 Dec 2024 Pengumuman LYNPARZA® (olaparib) demonstrated clinically meaningful prolonged survival benefit in early breast cancer in OlympiA Phase III trial
09 Dec 2024 Pengumuman Datopotamab deruxtecan granted breakthrough therapy designation in US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer
08 Dec 2024 Pengumuman Fixed-duration CALQUENCE plus venetoclax demonstrated superior PFS vs. standard of care in previously untreated CLL, with 77% of patients progression free at three years in AMPLIFY Phase III trial
06 Dec 2024 Pengumuman IMFINZI® (durvalumab) granted Priority Review in the US ​for patients with muscle-invasive bladder cancer
05 Dec 2024 Pengumuman IMFINZI® (durvalumab) approved in the US as first and only immunotherapy regimen for patients with limited-stage small cell lung cancer
25 Nov 2024 Pengumuman TRUQAP® (capivasertib) combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and clinically meaningful improvement in radiographic progression-free survival in CAPItello-281 Phase III trial
20 Nov 2024 Pengumuman AstraZeneca awards $3.5M for projects to improve access to healthcare for patients across the US
18 Nov 2024 Pengumuman GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study
12 Nov 2024 Pengumuman AstraZeneca’s 9M and Q3 2024 results
12 Nov 2024 Pengumuman AstraZeneca invests $3.5 billion in R&D and manufacturing in the United States
08 Nov 2024 Pengumuman TEZSPIRE met both co-primary endpoints in the Phase III WAYPOINT trial in patients with chronic rhinosinusitis with nasal polyps
07 Nov 2024 Pengumuman AstraZeneca showcases strength of hematology portfolio and pipeline at ASH 2024
18 Oct 2024 CNBC Merck says experimental RSV treatment protected infants in trial, paving way for potential approval
07 Oct 2024 Pengumuman AIRSUPRA® (albuterol/budesonide) demonstrated statistically significant and clinically meaningful reduction in the risk of severe exacerbations in patients with intermittent or mild persistent asthma in BATURA Phase III trial
03 Oct 2024 Pengumuman CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphoma
02 Oct 2024 Pengumuman Arcus Biosciences Announces Clinical Trial Collaboration Agreement to Evaluate Casdatifan in Combination with Volrustomig in Renal Cell Carcinoma
01 Oct 2024 Pengumuman ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
26 Sep 2024 Pengumuman TAGRISSO® (osimertinib) approved in the US for patients with unresectable, Stage III EGFR-mutated lung cancer
23 Sep 2024 Pengumuman Datopotamab deruxtecan final overall survival results reported in patients with metastatic HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial
Papar semua
Hasil Dividen (DY TTM) 1.93%
Purata Hasil Dividen 5T 2.46%
Nisbah Pembayaran 71.57%
Jangkaan Pembayaran Dividen Seterusnya Mar 2025
Tarikh EX Tarikh Pengumuman Tarikh Pembayaran Perincian
09 Aug 2024 25 Jul 2024 09 Sep 2024 0.5 Tunai
22 Feb 2024 08 Feb 2024 25 Mar 2024 0.985 Tunai
10 Aug 2023 28 Jul 2023 11 Sep 2023 0.465 Tunai
23 Feb 2023 09 Feb 2023 27 Mar 2023 0.985 Tunai
11 Aug 2022 29 Jul 2022 12 Sep 2022 0.465 Tunai
24 Feb 2022 10 Feb 2022 28 Mar 2022 0.985 Tunai
12 Aug 2021 29 Jul 2021 13 Sep 2021 0.45 Tunai
25 Feb 2021 11 Feb 2021 29 Mar 2021 0.95 Tunai
13 Aug 2020 30 Jul 2020 14 Sep 2020 0.45 Tunai
27 Feb 2020 14 Feb 2020 30 Mar 2020 0.95 Tunai
08 Aug 2019 29 Jul 2019 09 Sep 2019 0.45 Tunai
28 Feb 2019 14 Feb 2019 27 Mar 2019 0.95 Tunai
09 Aug 2018 26 Jul 2018 10 Sep 2018 0.45 Tunai
15 Feb 2018 02 Feb 2018 19 Mar 2018 0.95 Tunai
09 Aug 2017 28 Jul 2017 11 Sep 2017 0.45 Tunai
15 Feb 2017 02 Feb 2017 20 Mar 2017 0.95 Tunai
10 Aug 2016 28 Jul 2016 12 Sep 2016 0.45 Tunai
17 Feb 2016 05 Feb 2016 21 Mar 2016 0.95 Tunai
12 Aug 2015 30 Jul 2015 14 Sep 2015 0.45 Tunai
18 Feb 2015 09 Feb 2015 23 Mar 2015 1.9 Tunai
13 Aug 2014 31 Jul 2014 15 Sep 2014 0.9 Tunai
19 Feb 2014 07 Feb 2014 24 Mar 2014 1.9 Tunai
14 Aug 2013 01 Aug 2013 16 Sep 2013 0.9 Tunai
13 Feb 2013 31 Jan 2013 18 Mar 2013 1.9 Tunai
08 Aug 2012 26 Jul 2012 10 Sep 2012 0.9 Tunai
15 Feb 2012 02 Feb 2012 19 Mar 2012 1.95 Tunai
04 Aug 2011 28 Jul 2011 12 Sep 2011 0.85 Tunai
02 Feb 2011 27 Jan 2011 14 Mar 2011 1.85 Tunai
04 Aug 2010 29 Jul 2010 13 Sep 2010 0.7 Tunai
03 Feb 2010 28 Jan 2010 15 Mar 2010 1.71 Tunai
05 Aug 2009 30 Jul 2009 14 Sep 2009 0.59 Tunai
04 Feb 2009 29 Jan 2009 16 Mar 2009 1.5 Tunai
06 Aug 2008 31 Jul 2008 15 Sep 2008 0.55 Tunai
07 Feb 2008 04 Feb 2008 17 Mar 2008 1.35 Tunai
08 Aug 2007 27 Jul 2007 17 Sep 2007 0.52 Tunai
07 Feb 2007 01 Feb 2007 19 Mar 2007 1.23 Tunai
09 Aug 2006 27 Jul 2006 18 Sep 2006 0.49 Tunai
08 Feb 2006 02 Feb 2006 20 Mar 2006 0.92 Tunai
10 Aug 2005 29 Jul 2005 19 Sep 2005 0.38 Tunai
09 Feb 2005 27 Jan 2005 21 Mar 2005 0.645 Tunai
11 Aug 2004 22 Jul 2004 20 Sep 2004 0.295 Tunai
Papar semua

Hasil Dividen Tahunan

Tahun Dividen Tahunan ($) Kekerapan/Tahun Hasil %
2024 1.49 2 1.93
2023 1.45 2 2.15
2022 1.45 2 2.14
2021 1.40 2 2.40
2020 1.40 2 2.80
2019 1.40 2 2.81
2018 1.40 2 3.69
2017 1.40 2 4.04
2016 1.40 2 5.12
2015 2.35 2 6.92
2014 2.80 2 7.96
2013 2.80 2 9.43
2012 2.85 2 12.06
2011 2.70 2 11.67
2010 2.41 2 10.44
2009 2.09 2 8.91
2008 1.90 2 9.26
2007 1.75 2 8.17
2006 1.41 2 5.27
2005 1.03 2 4.22
2004 0.295 1 1.62
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2024 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda